📣 VC round data is live. Check it out!

HLB Life Science Valuation Multiples

Discover revenue and EBITDA valuation multiples for HLB Life Science and similar public comparables like Berry Corp, LGI Ltd., La Francaise de l'Energie, Beetaloo Energy Australia and more.

HLB Life Science Overview

About HLB Life Science

HLB Life Science Co Ltd and its subsidiaries are engaged in the medicare business, bio development business, medical device business, and drug distribution business. The company is a medical device for in vitro diagnostics.The main business is the Medicare business, which includes foot and manufacturing, quasi-drug component development, and finished product consignment production.


Founded

1998

HQ

South Korea

Employees

N/A

Website

hlb-ls.com

Financials (FY)

Revenue: $30M
EBITDA: ($55M)

EV

$350M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

HLB Life Science Financials

HLB Life Science reported last fiscal year revenue of $30M and negative EBITDA of ($55M).

In the same fiscal year, HLB Life Science generated ($327K) in gross profit, ($55M) in EBITDA losses, and had net loss of ($66M).


HLB Life Science P&L

In the most recent fiscal year, HLB Life Science reported revenue of $30M and EBITDA of ($55M).

HLB Life Science is unprofitable as of last fiscal year, with gross margin of (1%), EBITDA margin of (183%), and net margin of (218%).

See analyst estimates for HLB Life Science
Last FY202320242025202620272028
Revenue$30M$65M$68M$30M
Gross Profit($327K)($495K)($1M)($327K)
Gross Margin(1%)(1%)(2%)(1%)
EBITDA($55M)$15M$17M($55M)
EBITDA Margin(183%)23%25%(183%)
EBIT Margin(46%)(25%)(21%)(46%)
Net Profit($66M)($4M)$4M($66M)
Net Margin(218%)(6%)6%(218%)
Net Debt$95M---

Financial data powered by Morningstar, Inc.

HLB Life Science Stock Performance

HLB Life Science has current market cap of $254M, and enterprise value of $350M.

Market Cap Evolution


HLB Life Science's stock price is $2.09.

HLB Life Science share price decreased by 4.1% in the last 30 days, and by 37.4% in the last year.

HLB Life Science has an EPS (earnings per share) of $-0.54.

See more trading valuation data for HLB Life Science
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$350M$254M-5.5%-4.1%-19.1%-37.4%$-0.54

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

HLB Life Science Valuation Multiples

HLB Life Science trades at 11.6x EV/Revenue multiple, and (6.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for HLB Life Science

HLB Life Science Financial Valuation Multiples

As of June 3, 2026, HLB Life Science has market cap of $254M and EV of $350M.

HLB Life Science has a P/E ratio of (3.9x).

Last FY202320242025202620272028
EV/Revenue11.6x5.4x5.2x11.6x
EV/EBITDA(6.3x)23.1x20.4x(6.3x)
EV/EBIT(25.2x)(21.6x)(25.2x)(25.2x)
EV/Gross Profitn/mn/m(241.7x)n/m
P/E(3.9x)(64.2x)62.6x(3.9x)
EV/FCF(10.8x)(16.8x)(8.9x)(10.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified HLB Life Science Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

HLB Life Science Margins & Growth Rates

In the most recent fiscal year, HLB Life Science reported gross margin of (1%), EBITDA margin of (183%), and net margin of (218%).

See estimated margins and future growth rates for HLB Life Science

HLB Life Science Margins

Last FY20242025202720282029
Gross Margin(1%)(2%)(1%)
EBITDA Margin(183%)25%(183%)
EBIT Margin(46%)(21%)(46%)
Net Margin(218%)6%(218%)
FCF Margin(107%)(58%)(107%)

HLB Life Science Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth4%(55%)
Gross Profit Growth192%(77%)
EBITDA Growth13%(423%)
EBIT Growth(14%)(0%)
Net Profit Growth(203%)(1726%)
FCF Growth89%(18%)

Data powered by FactSet, Inc. and Morningstar, Inc.

HLB Life Science Operational KPIs

Access forward-looking KPIs for HLB Life Science
Last FY202320242025202620272028
S&M Expenses to Revenue7%4%4%7%
G&A Expenses to Revenue2%1%1%2%
R&D Expenses to Revenue10%6%5%10%
Opex to Revenue45%24%18%45%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

HLB Life Science Competitors

HLB Life Science competitors include Berry Corp, LGI Ltd., La Francaise de l'Energie, Beetaloo Energy Australia, Infinity Natural Resources, Horizon Oil, Montauk Renewables, Omega Oil & Gas, Imperial Ptrl and Archer.

Most HLB Life Science public comparables operate across Energy Production.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Berry Corp----
LGI Ltd.9.3x7.9x19.6x15.8x
La Francaise de l'Energie9.3x8.7x17.5x22.9x
Beetaloo Energy Australia58.4x49.8x(21.3x)(237.7x)
Infinity Natural Resources2.0x1.5x2.8x2.1x
Horizon Oil2.6x2.6x11.9x-
Montauk Renewables2.1x2.0x10.6x8.5x
Omega Oil & Gas3751.8x11402.9x(59.0x)(32.1x)

This data is available for Pro users. Sign up to see all HLB Life Science competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About HLB Life Science

When was HLB Life Science founded?HLB Life Science was founded in 1998.
Where is HLB Life Science headquartered?HLB Life Science is headquartered in South Korea.
Is HLB Life Science publicly listed?Yes, HLB Life Science is a public company listed on Korea Exchange.
What is the stock symbol of HLB Life Science?HLB Life Science trades under 067630 ticker.
When did HLB Life Science go public?HLB Life Science went public in 2008.
Who are competitors of HLB Life Science?HLB Life Science main competitors include Berry Corp, LGI Ltd., La Francaise de l'Energie, Beetaloo Energy Australia, Infinity Natural Resources, Horizon Oil, Montauk Renewables, Omega Oil & Gas, Imperial Ptrl, Archer.
What is the current market cap of HLB Life Science?HLB Life Science's current market cap is $254M.
What is the current revenue of HLB Life Science?HLB Life Science's last fiscal year revenue is $30M.
What is the current EV/Revenue multiple of HLB Life Science?Current revenue multiple of HLB Life Science is 11.6x.
Is HLB Life Science profitable?No, HLB Life Science is not profitable.
How many companies HLB Life Science has acquired to date?HLB Life Science hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies HLB Life Science has invested to date?HLB Life Science hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to HLB Life Science

Lists including HLB Life Science

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial